Arcus Biosciences, Inc.
PYRIDONE A2R ANTAGONISTS
Last updated:
Abstract:
Compound that inhibit at least one of the A.sub.2A and A.sub.2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A.sub.2A receptor and/or the adenosine A.sub.2B receptor.
Status:
Application
Type:
Utility
Filling date:
26 Jul 2019
Issue date:
3 Jun 2021